ME02470B - Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom - Google Patents
Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekomInfo
- Publication number
- ME02470B ME02470B MEP-2016-122A MEP2016122A ME02470B ME 02470 B ME02470 B ME 02470B ME P2016122 A MEP2016122 A ME P2016122A ME 02470 B ME02470 B ME 02470B
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer
- accordance
- nanoparticles used
- nanoparticles
- intra
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims 12
- 230000000973 chemotherapeutic effect Effects 0.000 title claims 3
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229960004679 doxorubicin Drugs 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- 238000001361 intraarterial administration Methods 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000002045 lasting effect Effects 0.000 claims 3
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims 3
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Manufacturing & Machinery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1.Nanočestice, naznačene time, što sadrže najmanje jedan hemoterapeutski antitumorski agens, najmanje jedan poli(alkilcijanoakrilat) i najmanje jedan ciklodekstrin, koji se upotrebljavaju za tretiranje raka, pri čemu se pomenute administriraju intravenoznom ili intra-arterijalnom infuzijom tokom najmanje 2 časa, pri čemu je najmanje jedan hemoterapeutski antitumorski agens doksorubicin ili neka njegova farmaceutski prihvatljiva so, pri čemu se doza doksorubicina kreće od oko 20 do oko 30 mg/m2.
2.Nanočestice koje se upotrebljavaju u skladu sa zahtevom 1, naznačene time, što doza doksorubicina iznosi oko 20 mg/m2.
3.Nanočestice koje se upotrebljavaju u skladu sa zahtevom 1, naznačene time, što doza doksorubicina iznosi oko 30 mg/m2.
4.Nanočestice koje se upotrebljavaju u skladu sa bilo kojim od zahteva od 1-3, naznačene time, što se administriraju primenom intravenozne ili intra-arterijalne infuzije koja traje između 2 i 24 časa.
5.Nanočestice koje se upotrebljavaju u skladu sa bilo kojim od zahteva od 1-3, naznačene time, što se administriraju primenom intravenozne ili intra-arterijalne infuzije koja traje između 4 i 12 časova.
6.Nanočestice koje se upotrebljavaju u skladu sa bilo kojim od zahteva od 1-3, naznačene time, što se administriraju primenom intravenozne ili intra-arterijalne infuzije koja traje oko 6 časova.
7.Nanočestice koje se upotrebljavaju u skladu sa bilo kojim od zahteva od 1-6, naznačene time, što najmanje jedan poli(alkilcijanoakrilat) je poliizoheksilcijanoakrilat.
8.Nanočestice koje se upotrebljavaju u skladu sa bilo kojim od zahteva od 1-7, naznačene time, što sadrže najmanje jedan hemoterapeutski agens u koncentraciji od 0.01 do 200 mg/g nanočestica, najmanje jedan ciklodekstrin u količini od 0.1 do 70% w/w i najmanje jedan poli(alkilcijanoakrilat) u količini od 1 do 25% w/w.
9.Nanočestice koje se upotrebljavaju u skladu sa bilo kojim od zahteva od 1-8, naznačene time, što pomenuti rak je čvrsti tumor ili neki hematopoetski tumor, preferirano izabran iz grupe koja obuhvata hepatocelularni karcinom, akutnu limfoblastičnu leukemiju, akutnu mijeloblastičnu leukemiju, hroničnu mijelogenu leukemiju, Hodgkin-ovu bolest, difuzni limfom velikih B-ćelija, sitnoćelijski rak pluća, kolorektalni rak, rak pankreasa, rak dojke, rak jajnika, rak materice, rak vrata materice, rak glave i vrata, rak mozga, rak bešike, multipli mijelom, neuroblastom, Edwing-ov sarkom, osteosarkom, sarkom mekog tkiva, rak štitaste žlezde, rak prostate, rak želuca, nefroblastom, Kaposi-ev sarkom, i ne-Hodgkins-ov limfom.
10.Nanočestice koje se upotrebljavaju u skladu sa bilo kojim od zahteva od 1-8, naznačene time, što pomenuti rak je hepatocelularni karcinom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305364.9A EP2508207B1 (en) | 2011-03-31 | 2011-03-31 | Nanoparticles loaded with chemotherapeutic antitumoral Drug |
| EP12713673.7A EP2691116B8 (en) | 2011-03-31 | 2012-03-30 | Nanoparticles loaded with chemotherapeutic antitumoral drug |
| PCT/EP2012/055756 WO2012131018A1 (en) | 2011-03-31 | 2012-03-30 | Nanoparticles loaded with chemotherapeutic antitumoral drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02470B true ME02470B (me) | 2017-02-20 |
Family
ID=44513370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-122A ME02470B (me) | 2011-03-31 | 2012-03-30 | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9763874B2 (me) |
| EP (2) | EP2508207B1 (me) |
| JP (1) | JP5523638B2 (me) |
| KR (1) | KR101578273B1 (me) |
| CN (2) | CN103379920A (me) |
| AU (1) | AU2012233666B2 (me) |
| BR (1) | BR112013019105A2 (me) |
| CA (1) | CA2822177C (me) |
| CY (1) | CY1117868T1 (me) |
| DK (2) | DK2508207T3 (me) |
| ES (2) | ES2424476T3 (me) |
| HR (2) | HRP20160708T1 (me) |
| HU (1) | HUE028465T2 (me) |
| IL (1) | IL227466A (me) |
| ME (1) | ME02470B (me) |
| MX (1) | MX344704B (me) |
| MY (1) | MY162339A (me) |
| PH (1) | PH12013501513A1 (me) |
| PL (1) | PL2508207T3 (me) |
| PT (1) | PT2508207E (me) |
| RS (1) | RS52880B (me) |
| RU (1) | RU2616494C2 (me) |
| SG (1) | SG193453A1 (me) |
| SI (1) | SI2691116T1 (me) |
| SM (1) | SMT201600197B (me) |
| WO (1) | WO2012131018A1 (me) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2508207B1 (en) | 2011-03-31 | 2013-05-08 | BioAlliance Pharma | Nanoparticles loaded with chemotherapeutic antitumoral Drug |
| EP2875072B1 (en) * | 2012-07-17 | 2017-03-15 | Dow Global Technologies LLC | Composition comprising an organic liquid diluent and a cellulose ether of very low viscosity |
| EP3476392A1 (en) * | 2014-02-28 | 2019-05-01 | Merck Sharp & Dohme Corp. | Method for treating cancer |
| JP2017514893A (ja) * | 2014-04-18 | 2017-06-08 | ファイザー・インク | 治療用ナノ粒子でがんを処置する方法 |
| US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
| US20160106722A1 (en) | 2014-10-21 | 2016-04-21 | Life Plus, LLC | Human therapeutic agents |
| US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
| US20240285592A1 (en) * | 2015-05-13 | 2024-08-29 | Ankh Life Sciences Limited | Human therapeutic agents |
| JP6938462B2 (ja) | 2015-07-28 | 2021-09-22 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 治療用化合物の脳への一方向送達のためのインプラント組成物 |
| WO2017046037A1 (en) | 2015-09-14 | 2017-03-23 | Onxeo | Nanoparticles loaded with active ingredients, their process of preparation and their uses |
| WO2017144543A1 (en) * | 2016-02-22 | 2017-08-31 | Onxeo | Combination therapies comprising immuno-oncology agents and belinostat |
| NO342271B1 (en) * | 2016-09-29 | 2018-04-30 | Sintef Tto As | A new drug delivery system for treatment of cancer |
| US10646540B2 (en) | 2016-11-18 | 2020-05-12 | City Of Hope | Peptide inhibitors of twist |
| CN106511365A (zh) * | 2016-12-17 | 2017-03-22 | 郑州郑先医药科技有限公司 | 一种治疗肝硬化的西药组合物 |
| CN118652192A (zh) | 2017-05-24 | 2024-09-17 | 德克萨斯州大学系统董事会 | 用于抗体药物缀合物的接头 |
| WO2019185685A1 (en) * | 2018-03-27 | 2019-10-03 | Sintef Tto As | Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer |
| WO2020207655A1 (en) | 2019-04-10 | 2020-10-15 | Sintef Tto As | Nanoparticles comprising copolymeric or homopolymeric compounds which comprise cyanoacrylate subunits |
| MX2019015508A (es) | 2019-12-18 | 2021-06-21 | Univ Guadalajara | Nanopartículas para el tratamiento del cáncer. |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310667A (en) | 1976-04-22 | 1982-01-12 | Agence Nationale De Valorisation De La Recherche (Anvar) | 2-N Quaternary ammonium salt derivatives of 9-hydroxy ellipticine |
| FR2775435B1 (fr) * | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
| JP5111729B2 (ja) * | 2002-06-05 | 2013-01-09 | ジェネンテック， インコーポレイテッド | 肝成長及び肝保護のための組成物と方法 |
| US20040202665A1 (en) * | 2002-07-01 | 2004-10-14 | Janette Lazarovits | Compositions and methods for therapeutic treatment |
| JP5201763B2 (ja) * | 2007-02-28 | 2013-06-05 | 昇一 城武 | 異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法 |
| US20090061009A1 (en) * | 2007-08-29 | 2009-03-05 | Joseph Schwarz | Composition and Method of Treatment of Bacterial Infections |
| EP2050747A1 (en) | 2007-10-12 | 2009-04-22 | BioAlliance Pharma | Dimers of harmol or of its derivatives and uses thereof |
| KR20100058662A (ko) * | 2007-10-26 | 2010-06-03 | 화이자 프로덕츠 인코포레이티드 | 개에게서 림프종을 치료하기 위한 이다루비신 |
| US20110003710A1 (en) * | 2008-02-28 | 2011-01-06 | John Hopkins University | Selectin ligands useful in the diagnosis and treatment of cancer |
| EP2153821A1 (en) * | 2008-08-06 | 2010-02-17 | BioAlliance Pharma | Oral formulations of camptothecin derivatives |
| EP2508207B1 (en) | 2011-03-31 | 2013-05-08 | BioAlliance Pharma | Nanoparticles loaded with chemotherapeutic antitumoral Drug |
-
2011
- 2011-03-31 EP EP11305364.9A patent/EP2508207B1/en not_active Not-in-force
- 2011-03-31 ES ES11305364T patent/ES2424476T3/es active Active
- 2011-03-31 RS RS20130322A patent/RS52880B/en unknown
- 2011-03-31 DK DK11305364.9T patent/DK2508207T3/da active
- 2011-03-31 PL PL11305364T patent/PL2508207T3/pl unknown
- 2011-03-31 PT PT113053649T patent/PT2508207E/pt unknown
-
2012
- 2012-03-30 MX MX2013007581A patent/MX344704B/es active IP Right Grant
- 2012-03-30 CN CN2012800092750A patent/CN103379920A/zh active Pending
- 2012-03-30 HU HUE12713673A patent/HUE028465T2/en unknown
- 2012-03-30 SG SG2013069091A patent/SG193453A1/en unknown
- 2012-03-30 PH PH1/2013/501513A patent/PH12013501513A1/en unknown
- 2012-03-30 KR KR1020137020892A patent/KR101578273B1/ko not_active Expired - Fee Related
- 2012-03-30 EP EP12713673.7A patent/EP2691116B8/en active Active
- 2012-03-30 HR HRP20160708TT patent/HRP20160708T1/hr unknown
- 2012-03-30 CN CN201510763081.5A patent/CN105233301A/zh active Pending
- 2012-03-30 WO PCT/EP2012/055756 patent/WO2012131018A1/en active Application Filing
- 2012-03-30 CA CA2822177A patent/CA2822177C/en not_active Expired - Fee Related
- 2012-03-30 ES ES12713673.7T patent/ES2577955T3/es active Active
- 2012-03-30 DK DK12713673.7T patent/DK2691116T3/en active
- 2012-03-30 ME MEP-2016-122A patent/ME02470B/me unknown
- 2012-03-30 US US14/009,021 patent/US9763874B2/en not_active Expired - Fee Related
- 2012-03-30 RU RU2013128934A patent/RU2616494C2/ru not_active IP Right Cessation
- 2012-03-30 SI SI201230615A patent/SI2691116T1/sl unknown
- 2012-03-30 JP JP2013550917A patent/JP5523638B2/ja not_active Expired - Fee Related
- 2012-03-30 AU AU2012233666A patent/AU2012233666B2/en not_active Ceased
- 2012-03-30 BR BR112013019105-8A patent/BR112013019105A2/pt not_active Application Discontinuation
- 2012-03-30 MY MYPI2013003362A patent/MY162339A/en unknown
-
2013
- 2013-07-14 IL IL227466A patent/IL227466A/en active IP Right Grant
- 2013-07-24 HR HRP20130702AT patent/HRP20130702T1/hr unknown
-
2016
- 2016-06-23 SM SM201600197T patent/SMT201600197B/it unknown
- 2016-06-23 CY CY20161100574T patent/CY1117868T1/el unknown
-
2017
- 2017-08-10 US US15/673,661 patent/US20170333341A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2014512356A5 (me) | ||
| JP2014512354A5 (me) | ||
| JP2012082234A5 (me) | ||
| HRP20160361T1 (hr) | Terapija u kombinaciji s antitumorskim alkaloidom | |
| JP2015512398A5 (me) | ||
| JP2015515475A5 (me) | ||
| NZ708506A (en) | Methods of treating bladder cancer | |
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| JP2014509659A5 (me) | ||
| Lu et al. | Phase II study on Javanica oil emulsion injection (Yadanzi®) combined with chemotherapy in treating patients with advanced lung adenocarcinoma | |
| JP2015502926A5 (me) | ||
| MX2013000779A (es) | Metodos para tratar cancer de mama utilizando 4-yodo-3-nitrobenzamida en combinacion con agentes antitumorales. | |
| Long et al. | Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients | |
| JP2014524469A5 (me) | ||
| JP2019521180A5 (me) | ||
| JP2016522202A5 (me) | ||
| JP2014525454A5 (me) | ||
| JP2014523398A5 (me) | ||
| JP2012107063A5 (me) | ||
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| HRP20201819T1 (hr) | Farmaceutski pripravak za liječenje raka koji sadrži laktatnu metalnu sol | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| JP2015518053A5 (me) | ||
| JP2013544892A5 (me) |